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Diabetic foot ulcerations have been extensively reported as vascular complications of diabetesmellitus associated with a high degree
of morbidity and mortality; in fact, some authors showed a higher prevalence of major, previous and new-onset, cardiovascular,
and cerebrovascular events in diabetic patients with foot ulcers than in those without these complications. This is consistent with
the fact that in diabetes there is a complex interplay of several variables with inflammatory metabolic disorders and their effect
on the cardiovascular system that could explain previous reports of high morbidity and mortality rates in diabetic patients with
amputations. Involvement of inflammatory markers such as IL-6 plasma levels and resistin in diabetic subjects confirmed the
pathogenetic issue of the “adipovascular” axis that may contribute to cardiovascular risk in patients with type 2 diabetes. In patients
with diabetic foot, this “adipovascular axis” expression in lower plasma levels of adiponectin and higher plasma levels of IL-6 could
be linked to foot ulcers pathogenesis by microvascular and inflammatory mechanisms. The purpose of this review is to focus on
the immune inflammatory features of DFS and its possible role as a marker of cardiovascular risk in diabetes patients.
1. Definition of Diabetic Foot Syndrome
Complications of foot ulcers are the major cause of hos-
pitalization and amputation in diabetic patients and lead
to significant health care costs as evidenced by the fact
that 20–40% of health care resources are spent on diabetes-
related diabetic foot [1, 2]. Diabetic foot syndrome (DFS)
is defined, according to the World health Organization, as
“ulceration of the foot (distally from the ankle and including
the ankle) associated with neuropathy and different grades of
ischemia and infection” [3]. It represents a serious long-term
complication of diabetes mellitus leading to amputations,
disability, and reduced quality of life.
2. Epidemiology of Diabetic Foot Syndrome
Approximately 82000 lower extremity amputations directly
related to diabetes are performed in the USA annually [4]. Of
these amputations, the majority (80%) have been preceded
by foot ulceration [5]. Foot ulceration is the most com-
mon single precursor to lower extremity amputation among
diabetics [6]. The presence of foot ulceration is considered
an important risk for morbidity, mortality, and disability
as supported by the fact that about 80% of nontraumatic
amputations are caused by the presence of diabetes and 85%
of these amputations are preceded by a foot ulceration [7]. An
estimated 15% of patients with diabetes will develop a lower
extremity ulcer during the course of their disease [8].
Several population-based studies indicate a 0,5% to 3%
annual cumulative incidence of diabetic foot ulcers [9]. The
prevalence of foot ulcers reported for a variety of populations
ranges from2% to 10% [10]. In a retrospectiveUS cohort study
of 8.905 patients with type 1 and type 2 diabetes, the incidence
of DFS was 5,8% over an observational period of 3 years [9].
In 15,6% of patients with DFS, lower limb amputations were
necessary and survival was significantly shortened and the
cost for 40–65-year-oldmale with new foot ulcers was $27987
for the two years after diagnosis. Pathogenesis of diabetic foot
ulcers is complex and multifactorial and it is well known that
these lesions rarely result from a single pathology. Several
causes work together leading to foot ulceration in diabetic
patients. The most common components of this detrimental
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pathway which lead to foot ulcerations include peripheral
neuropathy, foot deformity, abnormal foot pressures, limited
joint mobility, external trauma, peripheral vascular disease,
and peripheral edema (see Figures 5 and 6). A frequently
diabetes-related complication is neuropathy representing the
most important contributory cause in the pathway to ulcera-
tion.Diabetic peripheral neuropathy (DPN) is an impairment
of normal activities of the nerves throughout the body and
can alter autonomic, motor, and sensory functions [11]. In
sensory neuropathy, the lack of protective sensation makes
the foot vulnerable to unattended minor injuries caused by
an excess of pressure and mechanical or thermal injury.
According to an important prospective multicenter study,
sensory neuropathy was the most frequent component in the
causal sequence to ulceration in diabetic patients [12]. Other
forms of neuropathy may also play a role in foot ulceration.
Motor neuropathy alters the biomechanics and, gradually, the
foot anatomy causing foot deformities, limited joint mobility,
and altered loading of the foot. These disarrangements may
also alter the distribution of forces during walking and cause
reactive thickening of skin (callus) at sites of abnormal
load. Furthermore, ischaemic necrosis of tissues beneath the
callus leads to breakdown of skin and subcutaneous tissue,
resulting in a neuropathic ulcer. Autonomic neuropathy often
results in changes to the texture and turgor of the skin,
such as dryness and fissuring, creating a portal of entry for
bacteria. Autosympathectomy with consequent sympathetic
failure, arteriovenous shunting, and microvascular ther-
moregulatory disfunction impairs normal tissue perfusion
and microvascular responses to injury. Another disorder
contributing to the development of foot ulcers is peripheral
vascular disease that affects the blood vessels of small and
large sizes. Both macro- and microvascular diseases could
contribute to the consequences of peripheral vascular disease,
resulting in the inability of the dysvascular limb to heal
itself properly. The incidence and prevalence of peripheral
arterial disease (PAD) increase with age in both diabetic and
nondiabetic subjects and, in those with diabetes, increase
with the duration of diabetes. Hypertension, smoking, and
hyperlipidemia, which are frequently present in patients
with diabetes, contribute additional risk for vascular disease.
Studies have shown that peripheral vascular disease develops
at a younger age among patients with diabetes as compared
to the general population [10]. Measurement of the ankle-
brachial index (ABI), which represents the systolic blood
pressure at posterior tibial or dorsalis pedis level compared
with brachial blood pressure, can be used to define clinically
occlusive PAD. In patients with anABI< 0.90, the relative risk
has been reported to be 1.25 (95%CI 1.05, 1.47) for developing
an ulcer versus diabetic patients with a normal ABI [13].
Peripheral ischaemia resulting from proximal arterial disease
was given as a component cause in the pathway to ulceration
in 35% of cases in the two-centre study of causal pathways
[14]. A recent comparative study of peripheral arterial disease
in diabetic and nondiabetic patients confirmed that diabetic
patients had more distal disease and a poorer outcome with
respect to amputation and mortality [15]. The ischaemic foot
is red, dry, and often neuropathic and it is also susceptible to
pressure from, for example, footwear. Ulcerated diabetic foot
is a complex problem and it is the result of the interaction
of multiple causal factors such as neuropathy, peripheral
vascular disease, trauma, and infections. Neuropathy and
ischaemia are the initiating factors, most often together as
neuroischaemia, whereas infection is mostly a consequence.
It is possible to classify diabetic foot on a pathophysio-
logical and clinical way in: ischemic diabetic foot, neuropathic
ischemic foot, and infected diabetic foot, but this type of
classification in clinical practicemay appear too simple owing
to the fact that it is possible to distinguish more frequent
clinical variants with mixed features called neuroischemic
diabetic foot. All these clinical variants of DFS have typical
morphologic and clinical findings (see Figures 1, 2, 3, and 4).
In this review, we will reexamine some aspects of
immune-inflammatory markers involvement in diabetic foot
syndrome and the role of DFS as a possible marker of
cardiovascular risk in diabetic subjects.
3. Cardiovascular Morbidity and Mortality of
Disease in Diabetic Patients with DFS
Diabetic patients have a higher mortality compared with
patients without diabetes. Several studies have reported that
the rates of mortality and morbidity of CVD are 2–4 times
higher among patients with type 2 diabetes mellitus than in
nondiabetic subjects. Different studies also indicate that foot
ulcers in diabetic patients are related to a higher mortality. In
fact, diabetic foot is a major cause of morbidity in diabetic
patients, and the mortality rate is about twice that of patients
without foot ulceration [14, 16].
In a study [17] conducted by Pinto et al., these authors
hypothesized that patients with type 2 diabetes mellitus with
diabetic foot could have a worse prognosis in terms of faster
progression of cardiovascular damage and higher cardiovas-
cular morbidity. For this purpose, authors evaluated differ-
ences between subjects with type 2 diabetes mellitus with and
without diabetic foot in the following: (1) cardiovascular risk
profile, (2) cardiovascular morbidity prevalence by a retro-
spective evaluation, (3) prevalence of markers of subclinical
cardiovascular damage at the time of recruitment, and (4)
incidence of new-onset vascular events on a prospective anal-
ysis. They showed a higher prevalence of major cardiovascu-
lar risk factor, of subclinical markers of CVD, and of previous
and new-onset cardiovascular and cerebrovascular events in
diabetic patients with foot complications.These results could
explain previous reports of high morbidity and mortality
rates in diabetic patients with amputations [18–20].Themain
cause of death in patients with diabetes was coronary artery
disease (CAD) [18–20]. In this study, authors also reported a
higher prevalence of major cardiovascular risk factors such
as hypercholesterolemia, LDL plasma levels > 130mg/dL,
hypertriglyceridemia, and microalbuminuria/proteinuria in
diabetic foot patients compared with diabetic patients with-
out foot complications and this finding is consistent with the
hypothesis that diabetic foot syndrome in diabetic subjects
could represent a possible marker of cardiovascular risk.
They also reported that patients with diabetic foot were more
likely to have a cerebrovascular event (TIA and ischemic
stroke) both on a retrospective evaluation (previous TIA and
Journal of Diabetes Research 3
Figure 1: Neuropathic diabetic foot.
Figure 2: Neuropathic ulcers.
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Figure 3: Ischemic diabetic foot.
Figure 4: Infected diabetic foot.
ischemic stroke) and on a prospective evaluation (new onset
TIA and stroke on a 5-year follow-up). The most prevalent
subtypes of stroke were lacunar and LAAS subtype with
a slight higher prevalence of the lacunar subtype and this
finding could suggest a role of bothmicrovascular disease and
atheroscleroticmacroangiopathies, a determinant of vascular
morbidity in patients with diabetic foot. The higher cardio-
vascular risk associated with diabetic foot may be related to a
cumulative effect of the single risk factor linked to neuropathy
and PAD, which are two well-known medical conditions
recently associated with increased cardiovascular morbidity
[18, 19], but another explanation could be recognized in the
role of microangiopathy as a determinant of overall vascular
risk. Nevertheless, because the groups evaluated in this study
did not start with balanced CV risk factors and CV disease,
authors cannot exactly correct for so many other powerful
indicators especially with small numbers and relatively few
events; so our findings can only warn clinicians that diabetic
foot has to trigger a vital search for treatable cardiovascular
risk factors and diseases.
The diabetic foot syndrome is the most frequent cause
of hospitalization of diabetic patients and one of the eco-
nomicallymost demanding complications of diabetes. People
with diabetes have been shown to have higher mortality
than people without diabetes, but the cerebrovascular risk
profile of these patients is not fully evaluated. Another
study [21] has been conducted to evaluate the possible role
of diabetic foot as a cerebrovascular risk marker in type
2 diabetic patients. Authors enrolled 102 type 2 diabetes
patients with diabetic foot and 123 diabetic patients without
diabetic foot. Statistically significant differences were found
in the distribution of the main cardiovascular risk factors
with exception of hypertension. They observed a higher
prevalence of previous cerebrovascular events (transient
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Figure 5: Evolving foot in diabetics: from healthy foot to ischemic diabetic foot.
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Figure 6: Pathogenetic pathway linking diabetes to diabetic foot ulceration.
ischemic attack, ischemic stroke) and of incidence of new
onset cerebrovascular events at a 5-year follow-up. Regarding
clinical subtype of ischemic stroke classified according to
Trial of ORG 10172 in Acute Stroke Treatment (TOAST)
classification on a retrospective and prospective basis, we
observed a higher prevalence of both the lacunar and large
artery atherosclerosis subtype with a slight higher prevalence
of lacunar subtype in patients with diabetic foot. These find-
ings showed a worse cerebrovascular risk profile in diabetic
patients with diabetic foot than in diabetic subjects without
foot ulceration with a higher prevalence of cardiovascular
risk factors and of anamnestic cerebrovascular events and
incidence of new cerebrovascular events at a 5-year follow-
up.
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4. Cardiovascular Risk Factors in
Diabetic Patients
4.1. Microalbuminuria. Microalbuminuria is defined by the
detection of urinary albumin excretion rates of 30 to 300mg
in a 24 h urine collection. It is still the only anomaly of early
diabetic kidney that has prognostic value statements. In fact,
the appearance of microalbuminuria in diabetic patients is
a very important index for progression to the most serious
kidney disease. It represents a cardiovascular risk indicator
in diabetic populations and also in hypertensive and general
populations. Several studies and experimental data show in
fact that microalbuminuria is associated with an increased
risk for all-cause and cardiovascularmortality, cardiac abnor-
malities, cerebrovascular disease, and possibly PAD. In a
recent study conducted by our group [22], we have showed
the prevalence of microalbuminuria in patients with diabetic
foot was higher than in patients without diabetic foot. In
addition, we also showed a significant positive correlation
between some clinical and laboratory variables, including
microalbuminuria and the levels of interleukin 6 (IL-6) and
resistin which are adipocytokines that may contribute to
insulin resistance and to the development of inflammatory
responses.
4.2. Hypertension. Hypertension is defined, according to
the 1993 World Health Organization criteria, like a systolic
blood pressure 140mmHg and/or diastolic blood pressure
90mmHg in subjects who are not taking antihypertensive
medication. Diabetes mellitus and hypertension are both
common diseases and they represent two powerful indepen-
dent risk factors for cardiovascular, renal, and atherosclerotic
disease. The pathogenesis of hypertension in diabetes type 1
and type 2 is different. Diabetic nephropathy is considered
to be the main factor that contributes to the development
of hypertension in patients with diabetes mellitus type 1. In
the case of type 2 diabetes mellitus, hypertension is more
often essential and it is part of a plurimetabolic syndrome
in a context of insulin resistance. In all cases, hypertension
worsens the prognosis of patients, increasing the risk of both
macrovascular and microvascular complications. In fact,
in the framework of diabetes and hypertension accelerates
the development of diabetic retinopathy, nephropathy, and
peripheral vascular disease. In diabetic patients with hyper-
tension, blood pressure lowering helps to reduce significantly
the treatment of cardiovascular and renal events. Therefore,
it is necessary and appropriate treatment of hypertension in
diabetic patients, which should include nonpharmacological
interventions, drug therapy, regular monitoring of blood
pressure, and educational endeavors. A study conducted by
Pinto et al. [17] showed that the prevalence of hypertension
was similar in both groups of diabetic patients with and with-
out diabetic foot. In addition, we also showed a significant
positive correlation between some clinical and laboratory
variables, including hypertension and the levels of IL-6 and
resistin which are adipocytokines that may contribute to
insulin resistance and to the development of inflammatory
responses.
4.3. Dyslipidemia. There are numerous cardiovascular dis-
eases that occur in patients with diabetes, both type 1 or type
2. Dyslipidemia is one of the major risk factors for cardiovas-
cular disease in diabetes mellitus.The defects in the synthesis
and clearance of plasma lipoproteins are among the most
commonlymetabolic abnormalities that accompany diabetes.
The diabetic dyslipidemia, a characteristic pattern character-
ized by the presence of low levels of high-density lipoprotein
(HDL) cholesterol, hypertriglyceridemia, and postprandial
lipemia, which is observedmore frequently in type 2 diabetes,
is one of several factors that contribute to accelerating
macrovascular disease in diabetic patients. Among the dif-
ferent factors involved in developing of diabetic dyslipidemia
insulin effects on liver apoprotein production, regulation of
lipoprotein lipase (LpL), actions of cholesteryl ester transfer
protein (CETP), and peripheral actions of insulin on adipose
and muscle should be considered. The acknowledgment
and treatment of dyslipidemia are therefore two important
elements in the framework of a multidisciplinary approach
aimed at the prevention of coronary heart disease. According
to current guidelines for the prevention of coronary heart
disease in diabetic patients elevated, LDL-C is the primary
target of lipid-lowering therapy and statins are recommend
as the first-line treatment for diabetic dyslipidemia. However,
considering the complexity of the profiles of dyslipidemia in
diabetic patients, multiple drugs are often required to achieve
therapeutic targets. In addition, the other risk factors usually
associated with diabetes mellitus, such as hypertension,
hyperglycemia, and obesity, should be effectively managed to
reinforce the effects of lipid-lowering therapy. In our recent
study, we [17] showed a higher prevalence of dyslipidemia
in patients with diabetic foot ulcers than in those without
diabetic foot. In addition, we also showed a significant
positive correlation between some clinical and laboratory
variables, including dyslipidemia and the levels of IL-6 and
resistin which are adipocytokines that may contribute to
insulin resistance and to the development of inflammatory
responses.
5. Inflammation Markers and Their Role in
Cardiovascular Morbidity in DFS
In diabetes, there is a complex interplay of several variables
with inflammatory metabolic disorders and their effect on
the cardiovascular system. Simplified explanation may be
that inflammation increases insulin resistance, which in
turn leads to obesity, while perpetuates diabetes, high blood
pressure, prothrombotic state, and dyslipidemia [20]. Some
studies [23–25] suggest an interaction between hormones,
cytokines, and resistin. Nevertheless, the circulating levels
of adiponectin, which is the most abundant adipocytokine,
are reduced in conditions such as obesity, type 2 diabetes,
and coronary heart disease (CHD) [26–28]. In this con-
text, hypoadiponectinemia was associated with low HDL-
cholesterol (HDL-C) concentrations [26], decreased LDL
particle size [27], and increased markers of systemic inflam-
mation [29]. Jeffcoate et al. [30] suggested that in the diabetic
foot there is an inflammatory cascade through an increased
expression of proinflammatory cytokines, including tumor
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necrosis factor alpha (TNF-a) and interleukin-1b. Therefore,
it is very suggestive that diabetic foot is characterized by a
pronounced inflammatory reaction. Subclinical inflamma-
tion represents a risk factor for both type 2 diabetes and
several diabetes-related complications, but data on diabetic
neuropathies are scarce. Thus, some authors [31] investigated
whether circulating concentrations of acute-phase proteins,
cytokines, and chemokines differ among diabetic patients
with or without diabetic polyneuropathy. They measured 10
markers of subclinical inflammation in 227 type 2 diabetic
patients with diabetic polyneuropathy who participated in
the population-based MONICA/KORA Survey F3. Diabetic
polyneuropathy was diagnosed using the Michigan Neu-
ropathy Screening Instrument (MNSI). After adjustment
for multiple confounders, high levels of C-reactive protein
and IL-6 were most consistently associated with diabetic
polyneuropathy, high MNSI score, and specific neuropathic
deficits, whereas some inverse associations were seen for
IL-18. This study shows that subclinical inflammation is
associated with diabetic polyneuropathy and neuropathic
impairments and this association appears rather specific
because only certain immune mediators and neuropathic
impairments are involved.
Nevertheless, few data exist on the role of systemic
inflammation in patients with diabetic foot syndrome
although a low-grade immune activation represents an
important risk factor not only for the development of type
2 diabetes but also for several vascular complications of
diabetes such as macrovascular (myocardial infarction and
stroke) and microvascular ones (neuropathy and nephropa-
thy). The status of the immune system may be relevant
at several stages in the development of chronic wounds.
Immune activation may precede the incidence of a diabetic
foot ulcer in the same way that it precedes the manifes-
tation of type 2 diabetes and CHD. Since pro- and anti-
inflammatory processes are crucial in the different phases of
wound healing, it is well understood how the disturbances
of the immune system interfere with tissue homeostasis and
wound healing after themanifestation of ulcers leading to the
chronic, nonhealing wounds that are characteristic of DFS.
Weigelt et al. [32] evaluated the association between
foot ulcers and immune status in a cross-sectional study
in diabetic patients with and without foot ulcers by mea-
suring a range of immune mediators (acute-phase proteins,
cytokines, and chemokines) representing different aspects
of the immune system. These authors conducted this study
to compare circulating levels of these immune mediators
between both groups, to use multivariate regression models
to identify potential confounders of these associations, and
to investigate whether systemic immune activation was asso-
ciated with the severity of the foot ulcer. Circulating levels
of acute-phase proteins, cytokines, and chemokines were
measured in diabetic patients with an ulcer and without an
ulcer. Patients with an acute foot ulcer had higher levels of C-
reactive protein (CRP), fibrinogen, IL-6, macrophage migra-
tion inhibitory factor, macrophage inflammatory protein-
1𝛽, and interferon-𝛾-inducible protein-10 as well as lower
levels of RANTES (regulated on activation normal T-cell
expressed and secreted), whereas no differences were found
for IL-8, IL-18, and monocyte chemoattractant protein-1. In
multivariate models, size of ulcer, according to the University
of Texas classification, but not the grade of infection, was
independently associated with three markers of subclinical
inflammation (CRP, IL-6, and fibrinogen).
However, no study, to our knowledge, has evaluated
the role of adiponectin, resistin, and immune-inflammatory
biomarkers such as proinflammatory cytokines in patients
with diabetic foot compared with those without foot compli-
cations.
On this basis, Tuttolomondo et al. conducted a study
[22] with the aim to evaluate plasma levels of adiponectin,
resistin, and IL-6 in subjects with diabetic foot in comparison
with subjects without foot complications. Authors recruited
34 subjects with type 2 diabetes mellitus and foot ulceration
hospitalized for every condition related to diabetic disease,
but not for new vascular events (group A). As for controls, 37
patients with type 2 diabetes mellitus without foot ulceration
have been recruited (group B), all hospitalized for every
condition related to diabetic disease but not for new vascular
events. Adiponectin, resistin, and IL-6 serum levels were
evaluated. This study demonstrated that diabetic subjects
with diabetic foot showed in comparison with diabetics
without diabetic foot higher IL-6 and resistin plasma levels
and lower adiponectin plasma levels. Resistin, although pos-
tulated to contribute to insulin resistance,may also contribute
to inflammatory responses. Early investigations into the role
of resistin as an inflammatory factor demonstrated that
LPS (lipopolysaccharide) upregulated resistin expression in
rat WAT, 3T3-L1 adipocytes, and human monocytes [33].
Although some initial studies in animal models have pro-
duced discrepancies about the fact that proinflammatory
cytokines may regulate resistin, several recent human stud-
ies have supported the concept of inflammatory cytokine
mediation of resistin [34, 35]. Moreover, Osawa et al. [36]
reported that elevated serum resistin concentration appears
to be an independent risk factor for ischemic stroke, espe-
cially lacunar and atherothrombotic infarction in the general
Japanese population. In particular, in this study, authors
showed that the combination of high resistin and the presence
of either diabetes or hypertension increased the risk of
ischemic stroke.This is consistent with our findings regarding
the higher plasma levels of both IL-6 and resistin in diabetic
subjects with foot ulceration in comparison with diabetics
without foot complications. A recent study by Reilly and
coworkers [37] suggested resistin as a metabolic link between
inflammation and atherosclerosis. In contrast with resistin,
adiponectin that is known to enhance insulin sensitivity
and reduce atherosclerotic plaques, suppressed a resistin-
mediated rise in VCAM-1 and ICAM-1 [38]. Adiponectin
levels can be assessed by either of three variables: total
adiponectin, HMWA, and the SA index.
Recently, Almeda-Valdes et al. [39] showed that total
adiponectin, HMWA, and the SA index had similar utility
for the identification of the metabolic abnormalities. This
finding may stimulate the use of adiponectin in clinical and
epidemiological settings because the measurement of total
adiponectin is better standardized, cheaper, and more acces-
sible than the other two approaches. Hypoadiponectinemia
8 Journal of Diabetes Research
can be viewed as an early sign of a complex cardiovascular
risk factor predisposing to the atherosclerosis process as
well as a contributing factor accelerating the progress of
the atherosclerotic plaque. Adiponectin also exhibits anti-
inflammatory and atheroprotective actions in various tis-
sues by suppressing the expression of vascular adhesion
molecules and scavenger receptors, reducing the expression
of the inflammatory cytokine TNF-a, raising NO produc-
tion, and suppressing the proliferation and migration of
smooth muscle cells [40]. Furthermore, two receptors that
mediate adiponectin’s actions in fatty-acid oxidation and
glucose uptake, namely, ADIPOR1 and ADIPOR2 [41], have
been identified. Very recently, Halvatsiotis et al. [42] have
demonstrated for the first time that a sequence variant in the
intron 5 of the ADIPOR2, rs767870 among the eight studied,
is associated with cardiovascular disease in a population of
Greek individuals. Recent findings by Tuttolomondo et al.
[22] of lower median plasma levels of adiponectin in subjects
with diabetic foot could confirm this issue. Furthermore,
the same authors observed a significant negative correlation
between adiponectin plasma levels and some cardiovascular
risk factors such as hypertension, dyslipidemia, and clinical
variables indicating previous cardiovascular morbidity such
as previous TIA/stroke and incident vascular morbidity such
as neuropathy, microalbuminuria, and PAD and these find-
ings further suggest a possible role of hypoadiponectinemia
as a putative marker of cardiovascular morbidity both preva-
lent and incident. As several cytokines are also produced by
adipose tissue [43], it was postulated that an “adipovascular”
axis [44] may contribute to the increased risk of cardio-
vascular events in patients with type 2 diabetes. In patients
with diabetic foot, this “adipovascular axis” expression in
lower plasma levels of adiponectin and higher plasma levels
of IL-6 could be linked to foot ulcers pathogenesis by
microvascular and inflammatory mechanisms. Furthermore,
obesity correlates with metabolic complications of obesity.
Some authors [45] evaluated adipocyte volume and its rela-
tionship with TNF-a, IL-6, adiponectin, and high-sensitivity
C-reactive protein (hs-CRP) levels. Patients were divided into
4 groups: lean healthy controls [body mass index (BMI): 24.2
± 1.4 kg/m2], nondiabetic obese patients (30.2 ± 2.9), obese
(30.1± 3.2), and nonobese (22.2± 1.5) type 2 diabetic patients.
TNF-a, hs-CRP, adiponectin, and IL-6 levels were measured
preoperatively and SC fat specimens were obtained during
operation. In this study,mean adipocyte volumes were higher
in obese diabetic patients than in other groups. Mean TNF-a,
hs-CRP, and IL-6 levels were higher in obese diabetic patients
than in control subjects, obese nondiabetic, and nonobese
diabetic patients. Mean TNF-a levels of nondiabetic obese
patients were higher than the control group. Mean IL-6 levels
of diabetic and nondiabetic obese patients were higher than
control subjects. Mean adiponectin levels of control subjects
were higher than nondiabetic obese, nonobese diabetic, and
obese-diabetic subjects. Mean adiponectin levels of obese
diabetic patients were lower than nondiabetic obese subjects.
Mean hs-CRP levels were higher in diabetic patients whether
they were obese or not. Authors observed a positive corre-
lation between adipocyte size and TNF-a, IL-6, and hs-CRP
levels and negative correlation between adipocyte size and
adiponectin levels. These findings furtherly confirm the
existence of an adipose-inflammatory vascular axis strictly
involved in diabetic complications such as DFS owing to the
fact that adiposity and its related conditions, such as diabetes,
are at the same time pro-inflammatory and inflammatory
conditions.
Adipokines are markers of insulin resistance and play a
role in the atherosclerotic process [44].
Indeed, recent studies suggest that adiponectin may
play a role in the modulation of inflammatory vascular
response by inhibiting the expression of adhesion molecules
on endothelial cells [40], inhibiting endothelial cell NF-𝜅B
signaling [46], and suppressing macrophage function [47,
48]. Other studies showed that adiponectin suppressed the
TNF-a stimulated expression of E-selectin, VCAM-1, and
ICAM-1 in human endothelial cells [40, 46]. This suggests
further that adiponectin may be vasoprotective as reported
by other authors [47, 48] and negatively modulate the
atherogenic processes and that adiponectin has an interaction
with an important inflammatory cytokine such as TNF-a.
To evaluate the association of adipokines with the
macrovascular complications of type 1 diabetes melli-
tus, a study [47] has been conducted, evaluating serum
adiponectin, leptin, and resistin levels in type 1 dia-
betic patients and analyzing their relationship with carotid
intima media thickness (CIMT). The authors showed that
adiponectin levels in diabetics were higher and leptin levels
were lower than controls. Resistin levels were also higher
in the diabetic group compared to controls. Adiponectin
was also negatively correlated with CIMT, age, BMI, and
waist-to-hip ratio and positively with creatinine. Leptin
levels were correlated with total cholesterol and high-density
lipoprotein (HDL). Resistin was correlated with CIMT and
systolic blood pressure. Authors concluded that increased
adiponectin correlates negatively and resistin positively with
CIMT in type 1 diabetic patients, thus representing possible
candidate markers of adipose-inflammatory dysfunction also
in diabetic type 1 subjects and possible markers of cardiovas-
cular risk.
The pathophysiology of insulin resistance and atheroscle-
rosis share a common inflammatory basis. On this basis,
some authors [48] to test this hypothesis evaluated 40 patients
with a myocardial infarction (MI). Endothelium-dependent
(FMD (flow-mediated dilation)) and independent (NTG
(nitroglycerine)) vasodilatation (determined by ultrasound),
S(I) (insulin sensitivity index; determined by isoglycemic-
hyperinsulinaemic clamp) and serum levels of CRP (C-
reactive protein), TNF-a, IL-6, resistin, and adiponectin
(determined by ELISA) were measured. FMD, S(I), and
adiponectin levels resulted significantly lower in patients with
type 2 diabetes mellitus, whereas TNF-a and IL-6 levels have
been observed as significantly higher in the same diabetic
patients. Authors also reported that TNF-a concentrations
and brachial artery diameter were negatively correlated with
FMDwhereas S(I) was positively correlated with FMD.These
results indicate how endothelium is negatively impacted
in multiple ways by the diabetic state after an MI also
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suggesting endothelium as the main organ-target of adipose-
inflammatory dysfunction of diabetes.
Recently, Zietz et al. [46] reported that low levels of
adiponectin are associatedwith low levels ofHDL-cholesterol
and might represent an independent cardiovascular risk
factor, whereas high levels of adiponectin are associated
with high levels of HDL-cholesterol indicating a protective
risk profile. Furthermore, Tuttolomondo et al. [22] observed
significant either positive (for IL-6 and resistin) and negative
(for adiponectin) correlations in subjects with diabetic foot
between these immunoinflammatory and metabolic markers
and some clinical and laboratory variables and these corre-
lation further underline the relationships with inflammatory
background. Recently, Pinto et al. underlined [17] the role of
DFS to predict cardiovascular morbidity in diabetic patients,
even after correction for other well-known cardiovascular
risk factors. In our study, both univariate and multivariate
analyses showed the predictive positive role of resistin and
IL-6 plasma levels and a negative one of adiponectin towards
diabetic foot presence. Previous studies have shown the rela-
tionship between inflammatory cytokines and cardiovascular
morbidity in diabetic patients. Tuttle et al. [49] showed that
both IL-6 and TNF-a are chronically increased in diabetic
women with and without CVD compared to nondiabetic
women. The additive concentration of cytokines in diabetes
and CVD suggests a common inflammatory state in both
diabetes and CVD.
Thus, most recent evidences suggest that diabetic
atherosclerosis is not only a disease of hyperlipidemia simply,
but is also an inflammatory disorder. A study [50] has been
conducted to evaluate the prevalence of inflammatory
markers such as high-sensitivity C-reactive protein
(hsCRP), adiponectin, and nuclear factor-𝜅B (NF-𝜅B)
expression, in peripheral blood mononuclear cells in Indian
patients with type 2 diabetes mellitus with and without
macrovascular disease. Authors enrolled 29 consecutive
cases of type 2 diabetic patients with proven MVD (group
A), 28 matched cases without MVD (group B), and 14
healthy controls (group C) were evaluated for the clinical
parameters fasting blood glucose (FBG), 2 h postprandial
blood glucose (PPBG), glycosylated hemoglobin (HbA1c),
lipid profile, and the above-mentioned inflammatory
markers.
The authors reported that subjects with type 2 diabetes
showed higher hs-CRP and NF-𝜅B expression and lower
values of adiponectin compared to healthy controls. Group
A had significantly higher serum hs-CRP than group B
(𝑃 = 0.0001) despite comparable values of BMI, FBG,
2-h PPBG, HbA1c, and lipid parameters. Group A had
significantly higher serum hs-CRP and NF-𝜅B expression
and significantly lower levels of adiponectin than group
C. In Group A, serum adiponectin negatively correlated
with NF-𝜅B expression. In Group B, adiponectin values
correlated negatively with both FBG and 2-h PPBG. These
finding further suggest that patients with type 2 dia-
betes were in a proinflammatory state strictly related to
subsequent vascular complications such as diabetic foot
syndrome.
6. Discussion
Several diabetic foot problems including ulcerations, infec-
tions, and gangrene represent the most common cause of
hospitalization among diabetic patients and their manage-
ment, cost millions of euro every year, and place a tremen-
dous burden on the health care system. Peripheral sensory
neuropathy, deformity, and trauma are the most common
features underlying diabetic foot ulcers although other risk
factors such as calluses, edema, and peripheral vascular
disease have also been identified as etiological factors con-
tributing to the development of diabetic foot ulcers. Although
the pathogenesis of peripheral sensory neuropathy is still
poorly understood, there seem to be multiple mechanisms
involved, including the formation of advanced glycosylated
end products and diacylglycerol, oxidative stress, and activa-
tion of protein kinase C𝛽. The data linking glycemic control
and neuropathy are not as clear cut as those for retinopathy
because of the difficulty in identifying objective measures
to assess the many stages of neuropathy over time and
because the symptoms, or lack thereof, of neuropathy may be
misleading if assessed only through patient questionnaires.
Finally, the differential diagnosis of peripheral neuropathy is
quite large, and patients may have other etiologies as well.
The diabetic foot can be classified into the neuropathic foot,
characterized by the neuropathic ulcer, the Charcot joint,
and neuropathic oedema associated with a good circulation,
in which neuropathy predominates, and the ischaemic foot
in which atherosclerosis is the dominant factor leading
to a reduction in blood flow with absent pulses. In the
neuropathic foot, blood flow is increased, the vessels are still
and dilated as a result of medial wall calcification and there is
evidence for arteriovenous shunting. The neuropathic ulcer
characteristically develops on the plantar surface following
inflammatory autolysis and haematoma formation under
neglected callosities. Chiropody is therefore the mainstay of
treatment and recurrence is prevented by redistribution of
weight bearing forces by moulded insoles in special footwear.
Charcot osteoarthropathy is often preceded by fracturewhich
is a further a complication of diabetic neuropathy and pre-
cipitates the rapid bone and joint destruction of the Charcot
joint. The ischaemic foot is characterized by rest pain, ulcer-
ation, and gangrene. Medical management can be successful
in up to 72%, with the remainder needing arteriography to
assess suitability for arterial reconstruction or angioplasty.
In the diabetic leg, atherosclerosis is predominant in the
branches of the popliteal artery making arterial reconstruc-
tion difficult. Diabetes and its vascular complication have also
a clear inflammatory pathogenesis, but few studies evaluated
immunoinflammatory backgroundof diabetic foot syndrome
(DFS). Only few previous studies [17, 21, 22] evaluated
inflammatory markers such as cytokine and adipokines in
patient with diabetic foot. Hypoadiponectinemia can be
viewed as an early sign of a complex cardiovascular risk factor
predisposing to the atherosclerosis process and a contributing
factor accelerating the progress of the atherosclerotic plaque.
Adiponectin exhibits anti-inflammatory and atheroprotec-
tive actions in various tissues by suppressing the expression
of vascular adhesion molecules and scavenger receptors,
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reducing the expression of the inflammatory cytokine TNF-a,
raisingNOproduction, and suppressing the proliferation and
migration of smooth muscle cells. These data are consistent
with the findings reported by Tuttolomondo et al. [22] of
lower median plasma levels of adiponectin in subjects with
diabetic foot. Furthermore, we observed a significant negative
correlation between adiponectin plasma levels and some
cardiovascular risk factors such as hypertension, dyslipi-
demia, and clinical variables indicating previous cardiovas-
cular morbidity such as previous TIA/Stroke and incident
vascular morbidity such as neuropathy, microalbuminuria,
and PAD and these findings further suggest a possible role
of hypoadiponectinemia as a putative marker of cardio-
vascular morbidity both prevalent and incident. As several
cytokines are also produced thus an “adipovascular” axis
may contribute to the increased risk of cardiovascular events
in patients with type 2 diabetes. In patients with diabetic
foot this “adipovascular axis” expression in lower plasma
levels of adiponectin and higher plasma levels of IL-6 could
be linked to foot ulcers pathogenesis by microvascular and
inflammatory mechanisms. These findings further underline
the importance of inflammatory andmetabolic “milieu” such
as cytokines and adipose hormones in foot complications in
diabetics as already reported for other vascular complications
of diabetes [45, 51–61].
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